Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than G...(eutical products and services that make ...),Health

Date:6/8/2009

eutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

'/>"/>

SOURCE Novo Nordisk Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Needy Women and Children in Oakland County Get Big Boost for Free Health Care With Donation of Two-Year Lease for Chrysler 300C
2. Nyer Medical Group, Inc. Announces Sale of Companys Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract
3. Hearings Set for Monday as Part of Two-Year Democratic Process to Unite the Strength of California Long-Term Care Workers to Improve Their Lives and Better Serve Their Clients
4. IASIS Healthcare and Precyse Solutions Sign Two-Year Consulting Agreement
5. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
6. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
7. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
8. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
9. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
10. Accentia announces investigational new drug application for Revimmune for refractory MS
11. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract